A Phase 1/2 interventional study of TG4001 and Avelumab in HPV-Related Carcinoma, HPV-Related Cervical Carcinoma and HPV-Related Anal Squamous Cell Carcinoma, sponsored by Transgene. Active, not recruiting at 20 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Transgene · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study will consist of two parts :
In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 participants at increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will be no intra-participant dose escalation.
In the phase II part 1, evaluation of efficacy and further evaluation of safety of the combination of TG4001 and avelumab will be performed in a single arm of participants with recurrent or metastatic HPV-16 positive advanced malignancies.
In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will be performed in a randomized, open-label controlled study comparing TG4001 in combination with avelumab to avelumab alone in participants with HPV-16 positive advanced malignancies.
In both phases, evaluation of tumor response will be done locally according to RECIST 1.1.
All participants will be followed up until disease progression, death, or unacceptable toxicity, or study withdrawal for any reason, whichever occurs first.
10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.
This study's enrollment of 143 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Transgene is the lead sponsor of 18 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prior therapy:
Prior treatment for recurrent or metastatic disease is not required for:
Exclusion Criteria:
History of uncontrolled intercurrent illness including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: TG4001 · Drug: Avelumab
Applicable for Phase II part 2.
Drug: Avelumab
PhIb: Dose escalation PhII: Established RP2D for TG4001
Anti PD-L1
Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced Malignancies
Dose limiting toxicities (DLTs) includes the following: * Grade ≥ 3 drug related adverse event (AEs). However, fatigue, nausea/vomiting adequately treated with anti-emetics, endocrinopathies adequately controlled with one physiologic hormone replacement, skin toxicity and single laboratory values out of normal range without any clinical correlate, asymptomatic grade ≥3 lipase or amylase elevation, tumor flare defined as local pain, irritation, or rash localized at sites of known or suspected tumor or a transient Grade 3 infusion adverse event are excluded. * Liver function test abnormality: * AST or ALT \> 5 x ULN * Total bilirubin \> 3 x ULN * Concurrent AST or ALT \> 3 x ULN and total bilirubin \> 2 x ULN * Drug related AE requiring treatment interruption for more than 2 weeks
Time frame: From Day 1 to Day 28
Phase II Part 1: Overall Response Rate (ORR) by RECIST 1.1
Percentage of participants whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria over the the total number of evaluable participants. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.
Time frame: From treatment start, every 6 weeks for the first 9 months, then every 12 weeks up to 2 years.
Phase II Part 2 Cohort A: Progression Free Survival (PFS) by RECIST 1.1
PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.
Time frame: From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
Progression Free Survival (PFS) Phase II Part 2 Cohort A by Stratification
PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.
Time frame: From randomization: Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
Overall Response Rate (ORR) by Using RECIST 1.1 : Phase Ib, Phase II Part 2 Cohort A
Percentage of participants whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria over the the total number of evaluable participants. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.
Time frame: From treatment start (phase Ib) / randomization (phase II part 2) : Every 6 weeks for the first 9 months, then every 12 weeks up to 2 years.
Progression Free Survival (PFS) (Phase Ib, Phase II Part 1)
PFS is defined as the time from the date of first study treatment administration (Phase Ib, Phase II Part1) to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.
Time frame: From treatment start (phase Ib, phase II part 1): Every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 1 year.
Overall Survival (OS) : Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A
Time from the date of first study treatment administration Phase Ib, Phase II part 1 or time from the date of randomization Phase II part 2 Cohort A to the date of death due to any cause. If a patient is not known to have died survival will be censored at the date of last contact.
Time frame: From treatment start : Phase Ib, Phase II part 1 / from randomization: Phase II part 2 Cohort A through study completion, for an average of 4.5 years.
Duration of Overall Response (DoR): Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A
Duration of overall response in weeks (DoR) applies only to patients whose best overall response is CR or PR. The start date is the date of first documented response (CR or PR) and the end date is the date of event defined as first documented disease progression or death due to underlying cancer.
Time frame: From treatment start Phase Ib, Phase II part 1 / from randomization Phase II part 2 Cohort A : every 6 weeks for the first 9 months, then every 12 weeks through study completion, for an average of 2.5 years.
Proportion of Progressive Disease Phase II Part 2 Cohort B
Number of participants with liver metastases at baseline who has a documented disease progression as per RECIST1.1.
Time frame: From randomization: every 6 weeks up to 24 weeks.
From 01 September 2017 through 27 March 2024, a total of 361 participants were screened. Phase Ib: 01 September 2017 until 11 April 2018 Phase II part 1: 04 October 2018 until 10 August 2020 Phase II part 2: 03 Jun 2021 until 27 March 2024
| Milestone | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab |
|---|---|---|---|---|---|---|---|
| Started | 3 | 6 | 34 | 46 | 44 | 5 | 5 |
| Completed | 3 | 5 | 25 | 35 | 33 | 4 | 3 |
| Not completed | 0 | 1 | 9 | 11 | 11 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 4 | 4 | 4 | 1 | 2 |
| Withdrew: Clinical progression | 0 | 1 | 3 | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| Withdrew: Under trial intervention | 0 | 0 | 2 | 5 | 3 | 0 | 0 |
Dose limiting toxicities (DLTs) includes the following: * Grade ≥ 3 drug related adverse event (AEs). However, fatigue, nausea/vomiting adequately treated with anti-emetics, endocrinopathies adequately controlled with one physiologic hormone replacement, skin toxicity and single laboratory values out of normal range without any clinical correlate, asymptomatic grade ≥3 lipase or amylase elevation, tumor flare defined as local pain, irritation, or rash localized at sites of known or suspected tumor or a transient Grade 3 infusion adverse event are excluded. * Liver function test abnormality: * AST or ALT \> 5 x ULN * Total bilirubin \> 3 x ULN * Concurrent AST or ALT \> 3 x ULN and total bilirubin \> 2 x ULN * Drug related AE requiring treatment interruption for more than 2 weeks
| DLT | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab |
|---|---|---|
| Phase Ib: To Evaluate the Safety and Tolerability of the Combination of TG4001 Plus Avelumab in Participants With Recurrent or Metastatic HPV-16 Positive Advanced Malignancies | 0 | 0 |
Percentage of participants whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria over the the total number of evaluable participants. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.
| percentage of participants | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab |
|---|---|
| Overall Response Rate | 16.67 (5.64 to 34.72) |
| Disease Control Rate (DCR) | 46.67 (28.34 to 65.67) |
| Complete Response (CR) | 3.33 (0.08 to 17.22) |
| Partial Response (PR) | 13.33 (3.76 to 30.72) |
| Stable Disease (SD) | 30.0 (14.73 to 49.40) |
| Progressive disease (PD) | 53.33 (34.33 to 71.66) |
PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.
| Months | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab |
|---|---|---|
| Phase II Part 2 Cohort A: Progression Free Survival (PFS) by RECIST 1.1 | 3.0 (2.0 to 4.4) | 2.8 (1.7 to 4.2) |
PFS is defined as the time from the date of randomization to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.
| Months | Phase II Part 2 - Cohort A - Cervix Cancer - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Cervix Cancer - Avelumab | Phase II Part 2 - Cohort A - Anal Cancer - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Anal Cancer - Avelumab | Phase II Part 2 - Cohort A - Genital Cancer - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Genital Cancer - Avelumab |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) Phase II Part 2 Cohort A by Stratification | 4.3 (1.7 to 12.7) | 2.1 (1.4 to 2.8) | 3.0 (1.5 to 5.6) | 3.0 (1.4 to NA) | 1.6 (1.4 to 5.6) | 7.2 (2.8 to NA) |
Percentage of participants whose best overall response is either a Complete Response or a Partial Response according to Response Evaluation Criteria In Solid Tumors (RECIST v1.0) criteria over the the total number of evaluable participants. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.", or similar definition that is accurate and appropriate.
| percentage of participants | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab |
|---|---|---|---|---|
| Overall Response Rate (ORR) | 0.0 | 50.0 | 15.2 | 13.6 |
| Disease Control Rate (DCR) | 33.3 | 83.3 | 65.2 | 68.2 |
| Complete Response (CR) | 0.0 | 0.0 | 8.7 | 2.3 |
| Partial Response (PR) | 0.0 | 50.0 | 6.5 | 11.4 |
| Stable Disease (SD) | 33.3 | 33.3 | 50.0 | 54.5 |
| Progressive Disease (PD) | 66.7 | 16.7 | 34.8 | 31.8 |
PFS is defined as the time from the date of first study treatment administration (Phase Ib, Phase II Part1) to the date of first documented tumor progression or death due to any cause, whichever occurs first. If a participant has not had a PFS event at the cut-off date for analysis or at the date when a further antineoplastic therapy (other than those planned as study treatment in the protocol) is started, PFS will be censored at the date of last evaluable tumor assessment before the cut-off or start of further antineoplastic therapy.
| Months | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab |
|---|---|---|---|
| Progression Free Survival (PFS) (Phase Ib, Phase II Part 1) | 1.6 (1.4 to NA) | 12.0 (1.2 to NA) | 1.5 (1.4 to 5.5) |
Time from the date of first study treatment administration Phase Ib, Phase II part 1 or time from the date of randomization Phase II part 2 Cohort A to the date of death due to any cause. If a patient is not known to have died survival will be censored at the date of last contact.
| Months | Phase I - TG4001 5x10e6 Pfu | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab |
|---|---|---|---|---|---|
| Overall Survival (OS) : Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A | 5.6 (5.6 to NA) | 26.2 (8.7 to NA) | 10.3 (6.2 to 13.3) | 16.6 (10.5 to 21.7) | 16.5 (10.0 to 19.6) |
Duration of overall response in weeks (DoR) applies only to patients whose best overall response is CR or PR. The start date is the date of first documented response (CR or PR) and the end date is the date of event defined as first documented disease progression or death due to underlying cancer.
| Weeks | Phase I - TG4001 5x10e6 Pfu Avelumab | Phase I - TG4001 5x10e7 Pfu Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab |
|---|---|---|---|---|---|
| Duration of Overall Response (DoR): Phase Ib, Phase II Part 1, Phase II Part 2 Cohort A | — | 53.7 (40.7 to 239.7) | 25.1 (22.4 to 228.1) | 90.3 (12.1 to 138.4) | 55.9 (18.3 to 121.0) |
Number of participants with liver metastases at baseline who has a documented disease progression as per RECIST1.1.
| Participants | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab |
|---|---|---|
| Non progressive disease | 2 | 0 |
| Progressive disease <= 6 weeks | 2 | 1 |
| Progressive disease <= 12 weeks | 3 | 3 |
| Progressive disease <= 24 weeks | 3 | 3 |
Collected over All-cause mortality was assessed for up to 4.5 years. All non serious AEs not treatment related were reported from start of study treatment up to 30 days after last administration of study treatments through study completion for an average of 7 months. All treatment related non serious AEs and all SAEs were reported from start of study treatment up to 90 days after last administration of study treamtents through study completion for an average of 8.5 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I - TG4001 5x10e6 Pfu + Avelumab | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Phase I - TG4001 5x10e7 Pfu + Avelumab | 0/6 (0%) | 4/6 (66.7%) | 6/6 (100%) |
| Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | 12/34 (35.3%) | 18/34 (52.9%) | 34/34 (100%) |
| Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | 7/46 (15.2%) | 16/46 (34.8%) | 46/46 (100%) |
| Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | 5/44 (11.4%) | 18/44 (40.9%) | 43/44 (97.7%) |
| Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 PFU + Avelumab | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 PFU + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab |
|---|---|---|---|---|---|---|---|
| PneumoperitoneumGastrointestinal disorders | 1/3 | 0/6 | 0/34 | 0/46 | 0/44 | 0/5 | 0/4 |
| Pneumonia aspirationInfections and infestations | 1/3 | 0/6 | 0/34 | 0/46 | 0/44 | 0/5 | 0/4 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 1/3 | 0/6 | 0/34 | 0/46 | 0/44 | 1/5 | 0/4 |
| Disease progressionGeneral disorders | 0/3 | 0/6 | 10/34 | 0/46 | 1/44 | 0/5 | 0/4 |
| Pancreatitis acuteGastrointestinal disorders | 0/3 | 0/6 | 0/34 | 0/46 | 0/44 | 1/5 | 0/4 |
| General physical health deteriorationGeneral disorders | 0/3 | 0/6 | 2/34 | 1/46 | 0/44 | 1/5 | 0/4 |
| Ischaemic strokeNervous system disorders | 0/3 | 1/6 | 0/34 | 0/46 | 0/44 | 0/5 | 0/4 |
| Neurological symptomNervous system disorders | 0/3 | 1/6 | 0/34 | 0/46 | 0/44 | 0/5 | 0/4 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 1/6 | 2/34 | 1/46 | 0/44 | 0/5 | 0/4 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/3 | 1/6 | 0/34 | 0/46 | 0/44 | 0/5 | 0/4 |
| Event | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 PFU + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab |
|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/3 | 3/6 | 5/34 | 17/46 | 13/44 | 4/5 | 2/4 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 0/6 | 15/34 | 17/46 | 13/44 | 2/5 | 0/4 |
| AstheniaGeneral disorders | 2/3 | 3/6 | 9/34 | 16/46 | 14/44 | 1/5 | 2/4 |
| Injection site erythemaGeneral disorders | 1/3 | 4/6 | 8/34 | 12/46 | 0/44 | 1/5 | 0/4 |
| PyrexiaGeneral disorders | 2/3 | 3/6 | 14/34 | 18/46 | 8/44 | 2/5 | 0/4 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/6 | 4/34 | 9/46 | 8/44 | 1/5 | 2/4 |
| NauseaGastrointestinal disorders | 1/3 | 0/6 | 6/34 | 8/46 | 6/44 | 1/5 | 2/4 |
| FatigueGeneral disorders | 0/3 | 3/6 | 8/34 | 9/46 | 10/44 | 2/5 | 2/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/3 | 2/6 | 5/34 | 11/46 | 9/44 | 2/5 | 2/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/3 | 3/6 | 2/34 | 9/46 | 6/44 | 1/5 | 1/4 |
In phase I and phase II part 1: all participants included and who received any amount of study treatment will be included in the SAF. Any participant who is assigned a participants number but does not receive any study treatment will not be included in the SAF. In phase II part 2: all randomized participants who were administered at least one dose of IMP(s) according to the treatment allocated at randomization will be included in the SAF.
| Age, Categorical(Participants) | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 3 | 25 | 37 | 30 | 4 | 2 | 104 |
| >=65 years | 0 | 3 | 9 | 9 | 14 | 1 | 2 | 38 |
| Age, Continuous(years) | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 52.0 (45.0 to 56.0) | 65.5 (51.0 to 68.0) | 56.0 (48.0 to 67.0) | 57.0 (50.0 to 61.0) | 56.5 (46.5 to 66.5) | 43.0 (41.0 to 54.0) | 67.5 (57.0 to 75.5) | 56.0 (48.0 to 66.0) |
| Sex: Female, Male(Participants) | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 25 | 43 | 44 | 5 | 4 | 125 |
| Male | 1 | 4 | 9 | 3 | 0 | 0 | 0 | 17 |
| Race and Ethnicity Not Collected(Participants) | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab | Total |
|---|---|---|---|---|---|---|---|---|
| Count of participants | — | — | — | — | — | — | — | 0 |
| Region of Enrollment(participants) | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| France | 3 | 6 | 34 | 39 | 37 | 4 | 4 | 127 |
| Spain | 0 | 0 | 0 | 6 | 7 | 1 | 0 | 14 |
| Primary tumor location(Participants) | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab | Total |
|---|---|---|---|---|---|---|---|---|
| Cervical | 0 | 1 | 8 | 25 | 24 | 3 | 0 | 61 |
| Anal | 2 | 0 | 17 | 14 | 13 | 2 | 4 | 52 |
| Oropharyngeal | 1 | 4 | 5 | 0 | 0 | 0 | 0 | 10 |
| Vaginal | 0 | 1 | 3 | 2 | 3 | 0 | 0 | 9 |
| Vulvar | 0 | 0 | 1 | 4 | 4 | 0 | 0 | 9 |
| Penile | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| ECOG Performance Status(Participants) | Phase I - TG4001 5x10e6 Pfu + Avelumab | Phase I - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 1 - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort A - Participants Without Liver Metastases - Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab | Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab | Total |
|---|---|---|---|---|---|---|---|---|
| ECOG Status 0 | 0 | 4 | 10 | 18 | 11 | 3 | 1 | 47 |
| ECOG Status 1 | 3 | 2 | 24 | 28 | 33 | 2 | 3 | 95 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2017 to primary completion in Sep 2024, 84 months.
Results were first posted in Dec 2025, 1 year 2 months after primary completion.
Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 84 months is above that.
Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avelumab
Transgene